A claim can sound scientific and still leave your main question unanswered. Sermorelin advertising often starts with growth hormone biology, then moves quickly to better sleep, more energy, or a different body shape. The step between those statements deserves attention.
A useful evidence question is specific: did the same medicine, used in a comparable group of people, improve an outcome that matters? A study of another hormone treatment or a change in a laboratory marker may not answer that question.
Look for the exact treatment, population, comparison, and measured outcome behind a benefit claim.
Start with what was actually studied
Ask for the full research reference, not only a sentence in a sales page. Check the active ingredient, administration route, study size, and health conditions of the participants. A result in children with a diagnosed growth disorder is not automatically evidence for healthy older adults.
A compounded preparation may also differ from a historical product or a research formulation. FDA's explanation of compounding helps place those differences in context. Our introduction explains the distinction between a hormone signal and growth hormone itself.
A laboratory change is not the whole outcome
IGF-1 can be part of a clinician's assessment of the growth hormone system. A higher value alone does not demonstrate that someone sleeps better, avoids a fracture, or gains a meaningful improvement in everyday function.
Ask what the proposed treatment is meant to accomplish besides changing a test result. The Endocrine Society's deficiency guidance considers diagnosis and clinical context; it does not endorse choosing a number to pursue without understanding why it is low or whether treatment is warranted.
A testimonial leaves important variables unknown
Someone can sincerely feel better without establishing which part of a treatment plan caused the change. Sleep routines, nutrition, other medications, expectations, and time may all affect the story. A photo or enthusiastic review usually cannot separate those influences.
Use personal experiences to identify questions about support and convenience. Do not use them as a forecast of your result or as proof that a particular preparation is effective. The review library explicitly separates what providers advertise from what our research can verify.
Ask about uncertainty as well as possibility
A good clinical conversation has room for what is not known. Ask about potential harms, alternatives for the actual condition, and what findings would lead the clinician to recommend a different approach. Uncertainty should not disappear because an offer has a convenient monthly price.
Our safety guide covers how to bring existing diagnoses and medicines into that discussion. Our after-50 guide explains why common aging experiences do not automatically identify a hormone disorder.
Agree on the decision you will revisit
If a clinician proposes treatment, ask how they would judge whether continuing makes sense and when that conversation should happen. A plan based only on buying another supply can leave the original purpose unclear.
Write down the intended outcome, the follow-up arrangement, and the questions that remain unanswered. The appointment planner keeps those points easy to bring back to the visit. This publication has not clinically tested a product or established a benefit rate for any of the providers it reviews.
Follow the sources.
Provider pages establish advertised terms, not independently measured outcomes. General medical guidance does not validate every compounded preparation.
- FDA: Compounding questions and answers (opens in a new tab)
Compounded medicines differ from FDA-approved generic drugs.
- Mayo Clinic: Sermorelin injection information (opens in a new tab)
Rechecked September 23, 2026. Historical branded injection information; not the label for a present-day compounded preparation or evidence of adult anti-aging benefit.
- Endocrine Society: Adult growth hormone deficiency (opens in a new tab)
Diagnosis and treatment of established deficiency; not an endorsement of anti-aging prescribing.
- Endocrine Society: Growth hormone deficiency (opens in a new tab)
Childhood and adult disease sections are distinct; adult risk factors and prescribed GH replacement are the relevant material.
- FDA: Managing the benefits and risks of medicines (opens in a new tab)
General questions for evaluating benefit, follow-up and new medicines.
- FDA: Risks of compounded drugs (opens in a new tab)
Explains lack of FDA approval and the risks of poor-quality compounded preparations.
